These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 33378947)

  • 41. The Gut Microbiome and Hepatocellular Carcinoma.
    Akkız H
    J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
    Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
    Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions between bile salts, gut microbiota, and hepatic innate immunity.
    Schubert K; Olde Damink SWM; von Bergen M; Schaap FG
    Immunol Rev; 2017 Sep; 279(1):23-35. PubMed ID: 28856736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma.
    Wang YL; Liu C; Yang YY; Zhang L; Guo X; Niu C; Zhang NP; Ding J; Wu J
    FASEB J; 2024 Jul; 38(13):e23766. PubMed ID: 38967214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cross-talk between bile acids and intestinal microbiota in host metabolism and health.
    Nie YF; Hu J; Yan XH
    J Zhejiang Univ Sci B; 2015 Jun; 16(6):436-46. PubMed ID: 26055905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
    Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
    BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling.
    Wahlström A; Kovatcheva-Datchary P; Ståhlman M; Bäckhed F; Marschall HU
    Dig Dis; 2017; 35(3):246-250. PubMed ID: 28249261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity.
    Biagioli M; Carino A
    Handb Exp Pharmacol; 2019; 256():95-108. PubMed ID: 31119464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The double-edged sword of probiotic supplementation on gut microbiota structure in
    Nabavi-Rad A; Sadeghi A; Asadzadeh Aghdaei H; Yadegar A; Smith SM; Zali MR
    Gut Microbes; 2022; 14(1):2108655. PubMed ID: 35951774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5.
    Trammell SAJ; Svenningsen JS; Holst JJ; Gillum MP; Kuhre RE
    Molecules; 2020 May; 25(10):. PubMed ID: 32443832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota.
    Singh V; Yeoh BS; Abokor AA; Golonka RM; Tian Y; Patterson AD; Joe B; Heikenwalder M; Vijay-Kumar M
    Gut Microbes; 2020 Jul; 11(4):1077-1091. PubMed ID: 32223398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The gut microbiota - A vehicle for the prevention and treatment of hepatocellular carcinoma.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2022 Oct; 204():115225. PubMed ID: 35998677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically.
    Ma J; Hong Y; Zheng N; Xie G; Lyu Y; Gu Y; Xi C; Chen L; Wu G; Li Y; Tao X; Zhong J; Huang Z; Wu W; Yuan L; Lin M; Lu X; Zhang W; Jia W; Sheng L; Li H
    Gut Microbes; 2020 Sep; 11(5):1450-1474. PubMed ID: 32515683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bile acids and their receptors.
    Martinot E; Sèdes L; Baptissart M; Lobaccaro JM; Caira F; Beaudoin C; Volle DH
    Mol Aspects Med; 2017 Aug; 56():2-9. PubMed ID: 28153453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases.
    Jia ET; Liu ZY; Pan M; Lu JF; Ge QY
    J Zhejiang Univ Sci B; 2019 Oct.; 20(10):781-792. PubMed ID: 31489798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bile acids and FXR in functional gastrointestinal disorders.
    Mosińska P; Szczepaniak A; Fichna J
    Dig Liver Dis; 2018 Aug; 50(8):795-803. PubMed ID: 29908754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TGR5 signaling mitigates parenteral nutrition-associated liver disease.
    Willis KA; Gomes CK; Rao P; Micic D; Moran ER; Stephenson E; Puchowicz M; Al Abdallah Q; Mims TS; Gosain A; Yin D; Talati AJ; Chang EB; Han JC; Pierre JF
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G322-G335. PubMed ID: 31905022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bile Acids, Their Receptors, and the Gut Microbiota.
    Poland JC; Flynn CR
    Physiology (Bethesda); 2021 Jul; 36(4):235-245. PubMed ID: 34159805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.